A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropin-releasing hormone (GnRH) antagonist and building its global presence through new alliances.
Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix
US Refiling Planned
While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.
